XML 29 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Debt Financing (Tables)
 6 Months Ended
Jun. 30, 2012
Debt Financing [Abstract]  
Convertible notes, loans and contingent liabilities
The details of the convertible notes, loans and contingent liabilities are as follows at June 30, 2012:

 
 
Fixed
 
 
EUR/USD
 
Conversion
Rate for
1st-Issue
Principal
Duration
Interest
Price
Conversion
Lender
Date
Amount
(Note)
Rate
(stated)
Price
 
 
 
Norwood Secured Loan
04/03/2009
E
 2,500
(5
)
5% pa
$
US 0.50
1.2812
Round Enterprises Ltd.
08/04/2011
E
948
(7
)
10% pa
None(9)
N/A
Eardley Holding A.G.
08/04/2011
E
 237
(7
)
10% pa
None(9)
N/A
Round Enterprises Ltd.
11/08/2011
E
400
(8
)
10% pa
None(9)
N/A
Eardley Holding A.G.
11/08/2011
E
 100
(8
)
10% pa
None(9)
N/A
Round Enterprises Ltd.
02/17/2012
E
 1,000
(8
)
10% pa
None(9)
N/A
Eardley Holding A.G.
02/17/2012
E
200
(8
)
10% pa
None(9)
N/A
Round Enterprises Ltd.
04/19/2012
E
322
(10
)
10% pa
None(9)
N/A
Eardley Holding A.G.
04/19/2012
E
80
(10
)
10% pa
None(9)
N/A
Round Enterprises Ltd.
05/04/2012
E
480
(11
)
10% pa
None(9)
N/A
Eardley Holding A.G.
05/04/2012
E
120
(11
)
10% pa
None(9)
N/A
Total Short Term Principal Amounts
E
 6,387
Accrued Interest
E
 229
Total Short Term Notes
Payable to Related Parties
E
 6,616
 
Eardley Holding A.G. (1)
06/23/2006
E 
150
(2
)
10% pa
$
US 0.10
N/A
Anglo Irish Bank S.A. (3)
10/21/2007
E
 500
(2
)
10% pa
$
US 0.50
1.409
Round Enterprises Ltd.
12/10/2007
E
 1,500
(2
)
10% pa
$
US 0.50
1.4429
Round Enterprises Ltd.
01/22/2008
E
 1,500
(2
)
10% pa
$
US 0.50
1.4629
Round Enterprises Ltd.
04/25/2008
E 
2,000
(2
)
10% pa
$
US 0.50
1.5889
Round Enterprises Ltd.
06/30/2008
E
 1,500
(2
)
10% pa
$
US 0.50
1.538
Round Enterprises Ltd.
11/18/2008
E
 1,200
(2
)
10% pa
$
US 0.50
1.265
Round Enterprises Ltd.
02/9/2009
E
 1,500
(2
)
10% pa
$
US 0.50
1.294
Round Enterprises Ltd.
06/15/2009
E
 5,500
(2,4
)
10% pa
$
US 0.80
1.4045
Eardley Holding A.G.
06/15/2009
E
 100
(2,4
)
10% pa
$
US 0.80
1.43
Von Meyenburg
08/03/2009
E
 200
(2
)
10% pa
$
US 0.80
1.44
Round Enterprises Ltd.
10/13/2009
E
 2,000
(2
)
5% pa
$
US 0.25
1.4854
Round Enterprises Ltd.
12/18/2009
E
 2,200
(2
)
5% pa
$
US 0.25
1.4338
Total Long Term Principal Amounts
 
E
19,850
Accrued Interest
E
 6,369
Total Long Term Convertible Notes to Related Parties
E
26,219 
Total Convertible Notes to Related Parties
E
 32,835
Norwood Contingent Liability
E
 6,291
(6
) 
TOTAL LOANS, NOTES,AND CONTINGENT LIABILITY
E
 39,126
 
(1) Private investment company of Dr. Thomas Staehelin, member of the Board of Directors and of the Audit Committee of the Company. Face value is stated in U.S. dollars at $190.

(2) The earlier of: (i) the date that the Company has sufficient revenues to repay, or (ii) upon an event of default. The loan is secured against IP assets of Mymetics Corporation.

(3) Renamed Hyposwiss Private Bank Geneve S.A. and acting on behalf of Round Enterprises Ltd. which is a major shareholder.

(4) The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV.

(5) Under the terms of the acquisition of Bestewil BV, as part of the consideration, the Company issued to Norwood Immunology Limited ("NIL") a convertible redeemable note (the "Note") in the principal amount of E2,500 with a maturity date of April 1st, 2012 and bearing interest at 5% per annum. The note is secured against 1/3rd of Bestewil common stock. On April 19, 2012, Mymetics and Norwood Immunology Ltd (NIL) agreed to an amendment to the E2,500 loan agreement. The amended agreement resulted in the payment E402 on April 20, 2012 covering all the accrued interest due to NIL and a delay of the repayment of the E2,500 loan until September 30, 2012, with a 5% interest per annum starting from April 20, 2012. The repayment of the loan will be half in shares and half in cash and is contingent on an investment in the Company of not less than $20,000 by new investors. The conversion price is determined by reducing by 10% the price per share of the Company's common stock paid by the investors in connection with such an investment. In the case Mymetics is not able to close the investment of not less than $20,000 from new investors before or on September 30, 2012, the loan and accrued interest becomes immediately payable.
 
(6) Under the terms of the acquisition of Bestewil BV, as part of the consideration, the Company is committed to make further payments to NIL in the event that certain stated milestones for the development of vaccines are achieved. These have been considered on a risk probability basis.

(7) The loans expire the earlier of (i) June 30, 2012 or (ii) upon an event of default. The face values of the loans are stated in U.S. dollars at $1,200 and $300, respectively. These notes are under negotiation as they are expiring.

(8) The loans expire the earlier of (i) June 30, 2012 or (ii) upon an event of default. These notes are under negotiation as they are expiring.

(9) The conversion feature is contingent on an investment in the Company of not less than $20,000. The conversion price is determined by reducing by 10% the price per share of the Company's common stock paid by the investors in connection with such an investment.

(10) The loans expire the earlier of (i) September 30, 2012 or (ii) upon an event of default

(11) The loans expire the earlier of (i) July 31, 2012 or (ii) upon an event of default
Schedule of future payments of long term debt [Table Text Block]
Required future payments on long-term debt are as follows as of June 30, 2012:

2012
 
 
E
 
 
 
6,616
 
Contingent liability to Norwood (milestones and royalties)
 
 
E
 
 
 
6,291
 
Contingent on ability to repay
 
 
E
 
 
 
26,219
 
 
 
E
 
 
 
39,126